Opinions Glenn Paradis, BA, CFA
Axcan PharmaceuticalsAXP.TODON'T BUYMay 20, 2003
Its OK earnings wise. They are trying to make a hostile take over which looks expensive. Core business is OK.
Glenn Paradis, BA, CFAUnknown
$16.93
Stock price when the opinion was issued
biotechnologypharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
You might be interested:
TOP PICK
Part pharmaceutical and part drug development. Very profitable. Strong balance sheet and lots of cash flow. Generates about US$1.50 free cash flow every year. In a very stable gastro-intestinal market. They're also in-licence some drugs which gives them some pretty good upside. Trading at about US$14 with $1 a share free cash on the balance sheet.
Chris FernycOwned
biotechnologypharmaceutical
TOP PICK
A very focused (gastro intestinal) pharmaceutical company and as a result, it is very profitable. You pretty well get a free call option on a potentially block-buster drug called Itax. Huge market in North America.
Fred PynnOwned
biotechnologypharmaceutical
TOP PICK
Last news was that R&D spending would be higher than the street anticipated. Launching a product that could be a $200 million product.
Danny TomkaOwned
biotechnologypharmaceutical
TOP PICK
The entire US financial sector is attractive. Their brokerage sector is growing rapidly. Expects travel business will pick up.
John Sinkins, CFAOwned
biotechnologypharmaceutical
